Baeta - nā hiʻohiʻona o ka hoʻohana ʻia o nā mea hana antidiabetic

Pin
Send
Share
Send

ʻO ka ʻāpana antidiabetic no ka hoʻokele makua no Baeta i loko o ka papa o ka agonists incretin a kōkua iā ia e hōʻea i ka hoʻomehana glucose i loko o nā mea maʻi me ka mellitus type II.

ʻO ka Incretin kahi hormone i hana ʻia e ka mucosa ʻawa i ka pane ʻana i ka ʻai i ka meaʻai, kahi mea hōʻeuʻeu i nā mea huna o ka glucose i loaʻa i ka glucose.

ʻO ka hana o ka hana a Byet e hiki ai iā ʻoe ke hakakā me ka mellitus non-diabetes-mellitus i kekahi mau kuhikuhi i ka manawa hoʻokahi.

  • Mālama i ka mea huna o ka testosteroneagon, kahi e hoʻonui ai i ka kao o ka glucose i loko o ke kino.
  • Paipai i ka pancreatic β-cell e hoʻoulu i ka insulin.
  • Mālama i ka haʻalele o ka ʻai mai ka ʻōpū, e pale ana i ka hoʻokuʻu nui o ka glucose i loko o ke koko.
  • E alakaʻi pololei i nā kikowaena o ka līlū a me ka pōloli, e hōʻohi ana i ka momona.

Ke kōkua nei kēia kaʻina hana i ka nui o ka meaʻai i hoʻopau ʻia, ʻae i kahi mea maʻi maʻi maʻi e hōʻemi i ka paona a pale i nā lele i nā pae glucose koko, e mālama ana iā ia ma kahi pae physiological.

I kēia manawa, ke noiʻi nei nā poʻe loea i ka hopena o nā mimetin mimet e pili ana i nā nūna a me nā ʻoihana coronary. Ua hōʻike ʻia nā haʻawina holoholona holoholona i ka hoʻohana ʻana o nā lāʻau lapaʻau kelas tendetin e alakaʻi i kahi ʻāpana o ka hōʻola hou ʻana i nā pili panc-cell nā pancreatic.

Nā hana hana

ʻO ka ʻoihana huahana ʻo Beat the ʻo ia ʻo Eli Lilly a me ʻOihana Huila ʻoihana i hoʻokumu ʻia, i hoʻokumu ʻia i ka makahiki 1876 ma Indianapolis (USA, Indiana).

ʻO kēia ka hui lāʻau lapaʻau mua mua e hoʻomaka i ka hana ʻenehana i nā insulin i ka 1923.

Hoʻokumu ka hui a hana aku i nā lāʻau lapaʻau no nā poʻe i kūʻai kūleʻa ʻia ma nā hapa he haneli, a ma loko o nā aupuni 13 he mau mea hana no kā lākou hana.

ʻO ke kuhikuhi ʻelua o ka ʻoihana ka hana ʻana i nā lāʻau lapaʻau no nā pono o ka lāʻau lapaʻau.

Ua loaʻa no ʻo Lilly a me Company i Moscow ma mua o iwakālua mau makahiki. ʻO ke kumu o kāna ʻoihana ma Rūsia he mau pukana o nā lāʻau lapaʻau no ka mālamaʻana i ka maʻi diabetes, akā aia kekahi mau mea kūikawā: neurology, psychiatry, oncology.

Hōʻike

ʻO ka mea hoʻohana ikaika o ka lāʻau i ka 250 micrograms o exenatide.

ʻO ka nui ka sodium acetate trihydrate, glacial acetic acid, mannitol, metacresol a me ka wai no ka hoʻonāukiuki.

Loaʻa i ka Baeta ma ke ʻano o nā penehina syringe hoʻoneʻe me ka hopena waiwai no ka ʻoa ʻana ma lalo o ka ʻili 60 mau minuke ma mua o ka ʻai ʻana i ke kakahiaka a me ke ahiahi.

Baeta - 5 mcg

Nā Hōʻike

Hāʻawi ʻia ʻo Baeta i ka mālama ʻana i ka mellitus non-insulin-depend-type (type II) i mea e hoʻomaʻamaʻa ai i ka mana glycemic:

  • i ke ʻano o monotherapy - e pili ana i ke kua o ka pāʻai haʻahaʻa-low a me ka hana kino e hiki ai;
  • i ka hui hui ʻana:
    • as as an as sugar-lowering drug (metformin, thiazolidinedione, sulfonylurea derivatives);
    • no ka mea me ka metformin a me ka insulin basal.

I kēia hihia, pono paha nā derivatives o sulfonylurea e hoʻemi nui. Ke hoʻohana ʻana iā Byeta, hiki iā ʻoe ke hoʻemi iki i ka nui maʻamau ma 20% a hoʻoponopono iā ia ma lalo o ka kaohi o ka pae glycemia.

No nā lāʻau lapaʻau ʻē aʻe, ʻaʻole hiki ke hoʻololi ʻia ka hana mua o ka hoʻokele.

Kūkaha ʻia, ke noi ʻia ʻana o nā papa o ka lālani wikiō e hoʻohuihui ʻia me nā mea ʻē aʻe hypoglycemic e hoʻoikaika i kā lākou hana a e hōʻole i ka koho ʻana i ka insulin.

ʻAʻole hōʻike ʻia ka hoʻohana ʻana o exenatide no:

  • tsirairay hiki i ke aikoi o nā mea pili i ka lāʻau lapaʻau;
  • ʻO mellitus ka maʻi insulin-type (type I);
  • decompensated renal a nānā ʻole paha;
  • nā maʻi o ka ʻōnaehana o ka hana ʻana, hoʻopili ʻia e ka paresis (hoʻemi ʻia ka hana) o ka ʻōpū;
  • hapai a lactation;
  • ka lolo a mua paha o ka pancreatitis.

Mai kākau i nā keiki a hiki lākou i ka wā ʻelemakule.

Pono e mālama ʻia me ka hoʻohana pū ʻana o ka exenatide a me ka mākaukau waha e koi ai i ka hoʻihoʻi koke ʻana mai ka pānaʻi ʻana: pono e hana ʻia ma mua o hoʻokahi hola ma mua o ka maʻi o Bayet a i ʻole ia mau kīʻaha ʻole i pili ʻole i kāna alakaʻi.

ʻO ka pinepine o nā hanana ʻino i ka wā e hoʻohana ai ʻo Byet mai 10 a 40%, hōʻike ʻia lākou i ka maʻi nalo a me ka luaʻi ʻana i ka hoʻomaka mua o ka mālama ʻana. I kekahi manawa hiki ke hele mai nā hopena kūloko ma ka pūnaewele ʻōlelo.

Nā hiʻohiʻona o ka lāʻau

ʻO ka nīnau no ka hoʻokaʻawale ʻana iā Bayet me kahi hana hou, e like me ke kānāwai, hiki ke kū mai ma lalo o nā kūlana i lalo iho nei:

  • ʻaʻole hoʻemi ka lāʻau i ka glucose;
  • ua hōʻike ʻia nā hopena ʻaoʻao;
  • Ua kiʻekiʻe ke kumukūʻai.

ʻO ka lāʻau lapaʻau Baeta kūloko - nā lāʻau me nā mea lapaʻau i hōʻoia ʻia a i kūlike i ka kūlohelohe - ʻaʻole.

ʻO nā kikowaena piha i lalo o ka laikini mai Lilly a me Company ua hana ʻia e Bristol-Myers Squibb Co (BMS) a me AstraZeneca.

Kūkulu kekahi mau ʻāina ma o Byetu i lalo o ka hōʻailona lāʻau lapaʻau Bydureon.

ʻO Baeta Long kahi kikowaena hypoglycemic me ka mea hana pū aku ai (exenatide), he hana lōʻihi wale nō. ʻO ka hui kaulike o Baeta. Ke ʻano o ke hoʻohana - hoʻokahi ʻekahi subutaneus i kēlā me kēia 7 lā.

Ka hui pū kekahi o nā lāʻau lapaʻau e like me Victoza (Denemaka) - kahi lāʻau hoʻohaʻahaʻa i ke kōkō, ʻo ka hana ikaika ka liraglutide. Ma nā ʻano therapeutic, hōʻike a me nā contraindications, ua like like me Baete.

Hoʻokahi wale nō dosis i loaʻa i nā agonist incretin - kahi maʻi hou.

Hōʻike ka lua o ka papa o ka papa o ka huaʻai me nā lālani e pale i ka hana o ka enzyme dipeptidyl peptidase (DPP-4). Loaʻa lākou i nā ʻano molekiola a me nā waiwai pharmacological.

Hoʻokomo ka poʻe DPP-4 i loko o Januvia (Netherlands), Galvus (Switzerland), Transgenta (Kelemānia), Ongliza (USA).

E like me Baeta a me Victoza, hoʻonui lākou i nā kiʻekiʻe o ka insulin ma ka hoʻonui ʻana i ka lōʻihi o ka incretins, pale i ka hoʻouluʻana o ka glucagon a hoʻoulu i ka pancreatic cell regeneration.

Mai hoʻopilikia wale i ka helu o ka hoʻokuʻu ʻana o ka ʻōpū a ʻaʻole hoʻi e hāʻawi i ka lilo o ka kaumaha.

Ke hōʻike nei no ka hoʻohana ʻana o kēia ʻano o nā lāʻau i ka non-insulin-dependence diabetes mellitus (type II) i loko o ke ʻano monotherapy a i ʻole pū me nā lāʻau lapaʻau haʻahaʻa.

ʻO ka lawe ʻana i nā ʻōhua therapeutic ʻaʻole e hōʻemi i kahi kahe o ka kō koko koko, ʻoiai ka hiki ʻana o kona indexological index, pau ka hana ʻana i ka glucagon.

ʻO kekahi o nā pōmaikaʻi, ʻo kā lākou dosage form i ka ʻano o nā papa no ka hoʻopale waha, e hiki ai iā ʻoe ke komo i ka lāʻau i loko o ke kino me kaʻole e loaʻa ka maʻi.

Baeta a i ʻole Victoza: ʻoi aku ka maikaʻi?

Aia nā lāʻau ʻelua i ka hui like ʻole - ka syntetika analogues o ka peninen, nā hopena like therapeutic like.

Akā ʻoi aku ka hopena o Victoza e kōkua i ka hoʻemi ʻana o ke kaupaona o nā mea maʻi obese me ka maʻi II.

ʻOi aku ka lōʻihi o ko Victoza, a ke kuhikuhi ʻia e hāʻawi ʻia i nā inikini subcutaneous o ka lāʻau i hoʻokahi manawa i ka lā a i ʻole ka nānā ʻana o ka ʻai, aʻo Bayetu ke hoʻolauna ʻia ʻelua ʻelua i ka lā hoʻokahi ma mua o ka papaʻaina.

Ua kiʻekiʻe aʻe ke kumukūʻai o ke kūʻai aku ma Viktoza i nā lāʻau lapaʻau.

Ke hoʻoholo nei ke kauka komo i ka koho o ka lāʻau lapaʻau, me ka noʻonoʻo ʻana i nā hiʻohiʻona pilikino o ka mea maʻi, ka nui o nā hopena a me ka loiloi ʻana i ka pae o ka maʻa o ka maʻi o ka maʻi.

Nā wikiō pili

Pin
Send
Share
Send